May 1, 2020
FDA prioritizes BMS’s application for treatment of acute myeloid leukemia
U.S. FDA set target action date of September 3, 2020 Application based on results from the Phase 3 QUAZAR®-AML-001 study…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: acute myeloid leukemia
September 7, 2019
Selvita doses first acute myleoid leukemia patient testing CDK8 inhibitor
Selvita has dosed the first patient in its Phase 1b study of CDK8 inhibitor, SEL120, which is being initially investigated in the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS).
April 24, 2019
TC BioPharm Initiates Phase I Trial of Allogeneic Gamma Delta T Cell Therapy in Acute Myeloid Leukemia Patients
The trial, for treatment of patients suffering from AcuteMyeloid Leukemia (AML), is being conducted at the Institute ofHematology and Blood Transfusion (ÚHKT) in Prague, Czech Republic.
April 5, 2019
Onvansertib in Trovagene trial safe and well tolerated in difficult-to-treat relapsed or refractory AML patients
Trovagene said that additional data from its ongoing Phase 1b/2 study of onvansertib combined with standard-of-care chemotherapy in Acute Myeloid…
April 1, 2019
Trovagene expects additional evidence of clinical efficacy of onvansertib combined with chemoterapy in Acute Myeloid Leukemia
Preliminary efficacy data from Trovagene’s Phase 1b/2 study testing onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia (AML) is encouraging, in particular that it shows some complete and relatively durable responses, said lead investigator of the trial, Dr. Amer Zeidan.
March 13, 2018
ARC’s in combination with chemotherapy could be exciting development opportunity for AMLeukemia patients, MC of Wisconsin cleared to study Actimab-A+CLAG-M
A Phase 1 trial of Actimab-A in combination with CLAG-M for relapsed or refractory Acute Myeloid Leukemia (AML) patients, will be…
June 6, 2017
Celgene Corporation and Agios Pharmaceuticals report first results from acute myeloid leukemia study
Celgene Corporation and Agios Pharmaceuticals have reported new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral Idhifa (enasidenib) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-2 (IDH2) mutation.
December 29, 2016
argenx publishes data from acute myeloid leukemia drug study
Argenx (argenx) is currently working on a therapy for the treatment of acute myeloid leukemia (AML), and during the holiday season, the company has revealed how it is going.
December 16, 2016
RAC Approves Cellectis’s UCART123 Phase 1 study protocols in AML and BPDCN
Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), has announced the National Institute…
December 15, 2016
Argenx launches P I/II clinical trial for acute myeloid leukemia treatment
Argenx, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe…